News Business Sports Entertainment Life Obituaries Opinion
Jobs Homes Cars Classifieds Shopping

Search PB Blogs

Loading

Categories

891 posts categorized "Mayo Clinic"

August 23, 2016

Mayo's Noseworthy vs Cleveland Clinic's Consgrove

While Mayo Clinic and Cleveland Clinic vie for the top doctors and patients, their respective CEOs are also being compared.

Here's the breakdown of how Mayo Clinic's Dr. John Noseworthy and Cleveland's Dr. Toby Cosgrove have scored in Modern Healthcare's annual "Top 100 Influential People" list plus the salaries they were paid each year.


Rank in 2011
* Noseworthy - 71, earned $2 million
* Cosgrove - 56, earned $2.5 million

Rank in 2012
* Noseworthy - 17, earned $1.7 milion
* Cosgrove - 21, earned $3.1 million

Rank in 2013
* Noseworthy - 15, earned $1.9 million
* Cosgrove - 16, earned $3.2 million

Rank in 2014
* Noseworthy - 16, earned $2.3 million 
* Cosgrove - 72, earned $4.1 million

Rank in 2015
* Noseworthy - 8
* Cosgrove - 12

Rank in 2016
* Noseworthy - 30
* Cosgrove - 29

 

August 16, 2016

New biz incubator is up and running

08152016collider1The renovation of the 115-year-old Conley-Maass building at 14 Fourth St. SW by owners Traci and Hunter Downs is almost complete

The Bleu Duck Kitchen on the main level of the building is ready to open to the public next week.

0816collider2Meanwhile, upstairs, the Downs' new Collider business incubator is officially open for business under the management of Jamie Sundsbak. About one-third of the works spaces are contracted out so far, he said.

On Monday's opening day, Chris Lukenbill moved in his software development teams, which works for Bright Agrotech of Laramie, Wyo.

July 07, 2016

Broadway Flashback - early 2013 Broadway at Center plan

Following Wednesday's announcement about the delay in the financing for the now-$145 million Broadway at Center project, I decided to look at back an earlier version of that project rolled out by Titan Development and Investments in 2013.

Here's an article I filed on May 31, 2013 with an assist from Managing Editor Jay Furst. The rendering is of the version of Broadway at Center introduced at Titan's press conference:

Just a week after Mayo's Destination Medical Center plan was approved by the state, a Rochester developer announced plans today for a 25-story tower at the corner of South Broadway and East Center Street.

6a00d83451cc8269e2019102c4aed3970c-800wiThe Broadway at Center mixed-use project, proposed by Andy Chafoulias' Titan Development and Investments, would have about 30,000 square feet of Class A office space, a 150-room four-star hotel, 150 market-rent apartments, a "high-end grocery" and a Minnesota-branded steakhouse, among other attractions.

The announcement was made at a news conference this morning at Titan's offices in the Minnesota Biobusiness Center. Chafoulias didn't attend; the announcement was made by John Beltz, vice president of brand revenue development.

Titan is "poised for some very significant growth and contributions to Rochester," Beltz said, citing the company's planned restaurant and entertainment complex three blocks south at the C.O. Brown building site and a seniors apartment project further north on Broadway.

No cost estimate was provided for the Broadway at Center tower, and Beltz said the tower could go higher as planning proceeds -- possibly topping the Broadway Residences and Suites tower next door, which is the tallest building in Rochester and southern Minnesota. As planned, the building would have about 300,000 square feet of space and would be connected to the skyway system and a planned city parking ramp on the block.

The new building would be on the northwest corner of the block bounded by South Broadway, East Center Street, First Street Southeast and First Avenue Southeast. The Broadway Residence and Suites tower is on the southwest corner, and the new project would be on the current site of CJ's Midtown Lounge, Jakobson Management Co. and Ginny's Fine Fabrics.

The goal is to have a "hole in the ground" and construction underway next year, Beltz said. He declined to identify the hotel, restaurant and retail tenants who are in discussions with Titan but said in a news release that they're "finalizing negotiations with several recognizable Minnesota brands."

Rochester's lack of a top-tier hotel brand was often cited during the DMC legislative process as something the city needs to attract national and international medical visitors.

The announcement signals Andy Chafoulias taking the wheel of a project envisioned by his father, Rochester developer Gus Chafoulias, in 2007. That proposal was for a two-tower mixed-use project with retail, apartments and office space as well as possible space for University of Minnesota Rochester.

As with the previous version, Rochester architect Hal Henderson of HGA Architects and Engineers would direct the project design. Darren Schlapkohl, Titan vice president of development and construction management, said the project has "been in design for some time and continues to evolve."

Mayo's DMC initiative, which was announced in January and won legislative approval less than two weeks ago, is "an excellent addition to the vision" for Rochester, Beltz said, but Henderson said the Broadway at Center project has been at an advanced stage for at least six months.

June 29, 2016

Mayo Clinic tech doesn't fare well in Celyad/Cardio3 study

Sometimes lost opportunities are actually positive things. 
 
The City of Rochester really wanted rock star Belgium biotech Celyad/ Cardio3 to build a manufacturing facility here to handle the Mayo Clinic-created C-Cure stem cell cardiac treatment.
 
CelyadThat fell apart, when Celyad/Cardio3 pulled out of its plan to take over the fifth floor of the Minnesota Buiobusiness Center.
 
However, this week that looks like a good thing. Rochester make have ducked being stuck with a half built facility after the results of the latest study of C-Cure.
 
A Chart 1 Phase 3 study found that no difference between patients treated with the C-Cure and those given a placebo.
 
Here's how an article on the Seeking Alpha investment news site described the situation:
 

The failure of a pivotal trial of its heart failure cell therapy C-Cure, erased 38% from the Belgian company’s valuation this afternoon, an outcome that will make its search for a partner considerably harder.

Indeed, without a partner the project is effectively dead, as Celyad confirmed today that it would not conduct further clinical work alone.

------

The Chart-1 phase III study failed to show this: it recruited 271 patients with chronic advanced symptomatic heart failure, and compared C-Cure against sham treatment. The primary endpoint was a composite of mortality, morbidity, quality of life, six-minute-walk test and left ventricular structure and function at 39 weeks, and on this measure C-Cure patients failed to show any difference versus placebo.

 
That must be pretty disappointing after nine years of promising results.
 
 Celyad/Cardio3 licensed stem-cell research by Mayo Clinic's Dr. Andre Terzic and Dr. Atta Behfar in 2007. It was called Cardio3 Biosciences back then. They have collaborated for years on the cardiopoiesis technology the company uses to repair patients' hearts by re-programming their own stem cells to regenerate cardiac tissue. Mayo Clinic owned 2.69 percent of Celyad as of March 3, 2015.
 
However, Celayd bought an NKR-T cell platform from Celdara Medical in 2015. It appeared that the company very quickly turned away from C-Cure to focus on the new area. That is looking like the saving grace for Celyad today.
 

 All of which would have been disastrous if not for the presence of its fledgling immuno-oncology pipeline, which no doubt prevented an even bigger share price collapse.

-----

Further data updates are expected in the coming months, and indeed this afternoon Celyad’s chief executive, Christian Homsy, ended a conference call discussing the C-Cure results by flagging approaching good news in oncology. Given the relatively small amount paid to access this technology and the huge hopes for the adoptive T-cell space, investors could indeed soon forget the C-Cure failure.

June 27, 2016

Mayo Clinic announces Transplant Genomics deal

It looks like Mayo Clinic is joining forces with a Pleasanton, Calif.-based (previously of Massachusetts) firm to bolster its genetic testing to predict the success of organ transplants.

Logo-2-ret1Here's the vague description of the deal announced in a general press release this morning:

 

Transplant Genomics Inc. is collaborating with the Mayo Clinic Center for Individualized Medicine to develop, validate and commercialize diagnostic tests enabling personalized immunosuppression for solid organ transplant recipients. This multiyear collaboration includes an assessment of TGI's TruGraf test for renal transplant monitoring, a Mayo Clinic investment in TGI, and the co-development of new tests and technologies for additional targets, including exploratory studies in heart and liver transplantation.

This seems like this could be an interesting project. I wonder how long Mayo Clinic has been working with Transplant Genomics. 

It also would be fascinating to know how much Mayo Clinic is investing in TGI as well as how long this "multiyear" deal is slated to last.

 

 

 

June 13, 2016

Future use of ex-postal center still unclear

Almost a year since buying a former Med City mail processing center for $2.11 million, Mayo Clinic still is working out what to do with it.

3939Valleyhigh DriveMayo Clinic purchased the former U.S. Postal Service facility at 3939 Valleyhigh Drive in July 2015. The 72,662-square-foot center closed in January 2015, when mail processing was transferred to the Twin Cities.

When asked this week about its plan, the Mayo Clinic was pretty much the same as when it bought the building.

“No decisions have been made regarding the use of space at 3939 Valleyhigh Drive NW,” wrote Kelley Luckstein of Mayo Clinic Public Affairs on Friday in response to the query about the building.

The 19-year-old building could be adapted for a variety of purposes, such as an industrial laundry, a distribution center or light manufacturing. The center is described as "constructed of pre-stressed concrete and steel frames for high volume load distribution and contains a total of 23 dock doors; 10 overhead doors, 12 semi-truck docks and one grade door." 

 

June 07, 2016

For $300,000 upfront fee, Mayo Clinic licences cancer vaccine technology

May 31, 2016

A look at Mayo Clinic's NIH funding

It was announced last week that the National Institutes of Health awarded Mayo Clinic $142 million, spread out over five years, to a new federal Precision Medicine Initiative Cohort Program biobank.

NIH_Master_Logo_Vertical_2ColorThat made me think of a couple things. First, I remembered writing about the formation of Mayo Clinic Bioservices in 2014. It looks like that program is probably the core of this new project.

Next I wondered how $28.4 million a year or $142 million over five years measures up against Mayo Clinic's typical annual funding grants from NIH. Mayo Clinic has lots of money coming in from government contracts and grants from a variety of sources ranging from NIH to the Dept. of Defense.

Looking at just the NIH funding, this new grant is significant, but not not huge, in comparison to recent years.

Before this latest grant, NIH has already given Mayo Clinic $85.8 million in funding through 176 awards for 2016. The $28.4 million for this year will ramp it up to $114.2 million for 2016, which puts Mayo possibly on track for a record year. Here's the breakdown of Mayo's NIH grants in recent years.

• 2015 - 395 awards - $207.6 million

• 2014 - 401 awards - $201.2 million

• 2013 - 376 awards - $192.2 million

• 2012 - 380 awards - $205.2 million

• 2011 - 362 awards - $193.9 million






2016 - 176 awards - $85,878,422

 

May 20, 2016

Mayo Clinic Ventures looks to Israel for collaborations

Looking to help boost a variety of medical start-up businesses, Mayo Clinic Ventures is targeting collaborations and investments in Israel with a new program.

The goal of the Mayo Clinic Israeli Startup Initiative is to work with companies either through sponsored research grants or co-development.  

Flags"Co-development can include licensing of Mayo Clinic know-how or an investment," explained Timmeko Love, of Mayo Clinic Ventures. "It's about matching the right opportunities with Mayo Clinic know-how for collaboration. It's all about finding the right strategic fit."

Candidates for the Israeli Startup Initiative can include very early stage companies to ones that are much further along in development. They can work in any area of health care. 

"We're not limiting our options," Love said.

The project announced this week actually is a new phase of an existing Mayo Clinic initiative.

It has been active in Israel for about a year, partnering with the philanthropic Merage Institute. The California-based Merage Institute awards up to $150,000 in annual research grants for Israeli companies working with Mayo Clinic. The most recent recipient was EyeYon Medical, which makes a noninvasive medical device to treat corneal edema.

Mayo Clinic Ventures recently took on the Israel initiative and that has put co-development on the table. That new approach is being launched next week in Tel Aviv at IATI-Biomed, Israel’s largest life sciences and technology conference. Mayo teams will meet start-ups to study their technology, and then consider making investments or collaborations.

This is first time Mayo Clinic Ventures has focused on one whole country for business opportunities, despite its long history of international projects. Many might not be aware of it, but Israel is a logical candidate for a such a relationship.

"It's a natural next step for us," Love said.

Israel is considered to be the worldwide leader in innovation in medical devices, biopharma, software and other types of health-care businesses. The U.S imported $600 million of Israeli medical devices in 2011. In 2015, Israel housed 725 medical-devices businesses with an overall total of 1,380 life-sciences companies.

While California's Silicon Valley is known as the hottest spot in the world for business start-ups, Israel is recognized as a close second. A 2009 book, "Start-up Nation," documents how Israel, with a population of 7.1 million, generates more tech businesses than many much larger countries.

"It's kind of a national sport in Israel," said Guy David, a professor of health-care management at University of Pennsylvania’s Wharton School. He was born and raised in Israel and tracks its medical businesses closely.

David said Israel's required military service coupled with an environment that encourages questioning and taking risks is a big factor.

"Israel is hugely innovative. The innovative spirit starts at a very young age," he said.

While launching technology companies is a big focus in the country, the entrepreneurs all know the market for their products or services is elsewhere.

"There is no market in Israel. Israel is tiny," said David. "If they invent something, they know it has to be a global product."

Does that mean businesses partnering with Mayo Clinic could open offices or build facilities in Rochester?

"That certainly could be a possibility. We do look at an economic development when considering companies," said Love. "But it has to make sense for that company. There would need to be a business reason for it."

 

May 10, 2016

$100 million development proposed near Saint Marys

A more than $100 million housing and commercial development is proposed for a high-profile corner of Second Street Southwest, next to Mayo Clinic's Saint Marys campus.

Development1The plans call for a 13-story building with two levels of underground parking to be built on more than two acres at the southwest corner of 14th Avenue Southwest and Second Street.

The Brentwood on 2nd and the Ray-Mar Motel stand on that corner. The hotels, along with some nearby houses, will be demolished to clear the way for the project. The Brentwood also houses several businesses, including City Market, Charlie’s Eatery & Pub, A Shared Smile and the Healing Touch Spa.

05-09 4Brentwood enWhile some details could change as it goes through the permitting process, the proposal includes 359 housing units with 310 "luxury" apartments in the tower and 49 connected townhomes.

The plan also includes almost 900 parking spaces, some of which will be public. The townhomes will act as a buffer between the parking and the Folwell neighborhood. The developers hope eventually to connect the project to Saint Marys Hospital via subway.

The tower on the corner is expected to include about 20,000 square feet of commercial space, including 13,000 square feet on the street level that will encourage sidewalk traffic with a restaurant and retail.

Development3"This project is completely different from than anything that has ever been built in Rochester," said longtime local developer Ed Pompeian. "This beautiful building will be first thing you see coming into Rochester from the highway, heading into the medical corridor."

Pompeian, along with his son, Nick, is partnering with a Twin Cities real estate development firm,  Alatus LLC, to create this project. The Pompeians lead a local investment group, 1406 Second Street Associates, which controls the hotels and all of the property where the project will be built.

Mayo Clinic is not directly involved with the project at this point.

'An amazing beacon for the area'

Alatus is well-known for handling massive developments, such as Mayo Clinic Square, Latitude 45 Apartments and The Carlyle condos in Minneapolis. It is led by founder Bob Lux.

"I think it's going to serve as an amazing beacon for the area," said Chris Osmundson, the Alatus senior development associate working on the project. "In real estate, it's always location, location, location, and this one's got it."

The Pompeians and Alatus have been working on this plan for about two years. They now are bringing it to the city for pre-development meetings, followed by the approval process. If everything goes well, they could start clearing the site for construction sometime this summer or early fall.

Estimating a 16- to 18-month construction period, Osmundson said it's possible the project could be finished by spring 2018.

This is the first major project pitched for that area since the implosion of a proposed Holiday Inn hotel complex late last year. That project struggled though the planning process and was criticized by some neighborhood groups.

However, these developers are optimistic, after getting positive feedback from the Folwell, Kutzky and Historic Southwest neighborhood associations.

"It was very refreshing for everybody. Support was literally unanimous from the neighborhoods. Great things can happen, if you take the proper steps," said Nick Pompeian.

Talks started more than a year ago

Don Nordine, president of the Folwell Neighborhood Association, said the developers started talking to his group about a year and a half ago.

"We like the project, even though it is really big," he said. Folwell includes 200 houses, while the project will have 359 apartments and townhomes.

While the group supports the project, that doesn't mean they still don't have some concerns, said Nordine. The public parking aspect of the development has residents worried about traffic.

"The city and the developer have to get this right. We want this to keep this neighborhood residential and quiet. I think they are open and honest, but the devil is in the details," Nordine said.

Jesse Welsh, president of the Kutzky Park Neighborhood Association, is also positive about her interaction with Alatus and the Pompeians so far. While they have not been able to schedule an official presentation with her association yet, Welsh sat in on a Folwell meeting and spoke with Lux. She plans to brief her association on the project at a neighborhood meeting tonight. Members of the independent Imagine Kutzky advocacy group also sat in on meetings and were supportive of what they heard, she said.

Traffic is also a concern for the Kutzky neighborhood, but overall, Welsh was pleased with Lux's approach.

"What impressed me the most was how well they've worked with Folwell. They understand how critical it is to work with the neighborhood," she said.